PRIMARY STUDY
AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner
Key Findings: Using hippocampal neurons and mouse models of pain and gastric motility, this study concludes that AM841 via CB1 receptors significantly reduced gastric motility. The effect was more pronounced under stress conditions. This may provide future therapeutic targets for disorders of gastrointestinal mobility like colitis and irritable bowel syndrome.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Canada
Year of Pub: 2015
Cannabinoids Studied: AM-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, CB1 agonist, CB2 antagonist
Route of Administration: In vitro
Citation: Keenan CM, et al. AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner. Br J Pharmacol. 2015; 172:2406-18. doi: 10.1111/bph.13069
Authors: Keenan CM, Storr MA, Thakur GA, Wood JT, Wager-Miller J, Straiker A, Eno MR, Nikas SP, Bashashati M, Hu H, Mackie K, Makriyannis A, Sharkey KA
